Needle-free injections directly target vaccine hesitancy by removing one of its primary psychological barriers—needle-induced ...

Intra-Cellular’s promising clinical-stage pipeline includes treatments for a wide range of neurological indications.

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...

Chicago, IL – January 15, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks ...

Jan. 2, 2025 — Patients diagnosed with late-stage or metastatic breast cancer have a statistically significant increased risk of pre-diagnosis cardiovascular disease (CVD) compared to those with ...

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

Johnson & Johnson strengthens its neuroscience portfolio by acquiring Intra-Cellular Therapies, expanding its focus on CNS ...

Beyond sidestepping people’s fear of needles, these vaccines would also make it easier to store and distribute ahead of ...

By Bhanvi Satija and Puyaan Singh (Reuters) -Johnson & Johnson said on Monday it will buy neurological drugmaker ...

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...

Johnson amp Johnson JampJ the American multinational pharmaceutical biotechnology and medical technologies corporation agreed to acquire men ...